Page 34 - Read Online

Page 14 of 18 Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64

risk of chronic kidney disease. Ann Hepatol 2024;29:101512. DOI PubMed
21. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int
2024;44:1567-74. DOI PubMed
22. Pennisi G, Infantino G, Celsa C, et al. Clinical outcomes of MAFLD versus NAFLD: a meta-analysis of observational studies. Liver
Int 2024;44:2939-49. DOI PubMed
23. Li M, Xie W. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes? J
Hepatol 2024;80:e53-4. DOI PubMed
24. Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver
disease. Nat Rev Gastroenterol Hepatol 2023;20:764-83. DOI PubMed
25. Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol
2018;13:321-50. DOI PubMed
26. Arab JP, Addolorato G, Mathurin P, Thursz MR. Alcohol-associated liver disease: integrated management with alcohol use disorder.
Clin Gastroenterol Hepatol 2023;21:2124-34. DOI PubMed
27. Israelsen M, Torp N, Johansen S, Thiele M, Krag A. MetALD: new opportunities to understand the role of alcohol in steatotic liver
disease. Lancet Gastroenterol Hepatol 2023;8:866-8. DOI PubMed
28. Association for the Study of the Liver (EASL); Electronic address: easloffice@easloffice.eu; European Association for the Study of
Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL).
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease
(MASLD). J Hepatol 2024;81:492-542. DOI PubMed
29. Petrie E, Gray M, Bril F. Metabolic characteristics of patients with MetALD: caveats of a new definition. Liver Int 2024;44:2929-38.
DOI PubMed
30. Ciardullo S, Mantovani A, Morieri ML, Muraca E, Invernizzi P, Perseghin G. Impact of MASLD and MetALD on clinical outcomes:
a meta-analysis of preliminary evidence. Liver Int 2024;44:1762-7. DOI PubMed
31. Pennisi G, Enea M, Romero-Gomez M, et al. Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH)
patients with fibrosis: a comparative analysis of various risk stratification criteria. Hepatology 2024;79:912-25. DOI PubMed
32. Talamantes S, Lisjak M, Gilglioni EH, Llamoza-Torres CJ, Ramos-Molina B, Gurzov EN. Non-alcoholic fatty liver disease and
diabetes mellitus as growing aetiologies of hepatocellular carcinoma. JHEP Rep 2023;5:100811. DOI PubMed PMC
33. Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two
prospective cohort studies. Hepatology 2018;67:1797-806. DOI PubMed PMC
34. Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in
adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med 2019;17:95. DOI
PubMed PMC
35. Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty
liver disease. Hepatology 2020;71:808-19. DOI PubMed
36. Habib S. Metabolic dysfunction-associated steatotic liver disease heterogeneity: need of subtyping. World J Gastrointest
Pathophysiol 2024;15:92791. DOI PubMed PMC
37. García-Nieto E, Rodriguez-Duque JC, Rivas-Rivas C, et al. Clinical and molecular characterization of steatotic liver disease in the
setting of immune-mediated inflammatory diseases. JHEP Rep 2024;6:101167. DOI PubMed PMC
38. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
Gastroenterology 2018;155:1828-37.e2. DOI PubMed PMC
39. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic
syndrome? Metab Target Organ Damage 2024;4:10. DOI
40. Schwärzler J, Grabherr F, Grander C, Adolph TE, Tilg H. The pathophysiology of MASLD: an immunometabolic perspective. Expert
Rev Clin Immunol 2024;20:375-86. DOI PubMed
41. Breasted JH. The edwin smith surgical papyrus. Available from: https://isac.uchicago.edu/sites/default/files/uploads/shared/docs/oip4.
pdf. [Last accessed on 11 Nov 2024].
42. Ebbell B. The Papyrus Ebers: the greatest Egyptian medical document. Levin & Munksgaard;1937. Available from: https://search.
worldcat.org/zh-cn/title/The-Papyrus-Ebers-:-the-greatest-Egyptian-medical-document/oclc/5435947. [Last accessed on 11 Nov
2024].
43. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI PubMed
44. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. DOI PubMed
45. Senga SS, Grose RP. Hallmarks of cancer-the new testament. Open Biol 2021;11:200358. DOI PubMed PMC
46. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33. DOI PubMed
47. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. DOI PubMed
48. Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and
treatment. Nat Rev Gastroenterol Hepatol 2023;20:487-503. DOI PubMed
49. Molinari M, Kaltenmeier C, Samra PB, et al. Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a
systematic review and meta-analysis of 7226 patients. Ann Surg Open 2021;2:e065. DOI PubMed PMC
50. Chin KM, Prieto M, Cheong CK, et al. Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic